Skip to main content

Europe Viscosupplementation Market Expected to Expand at a Steady 2023-2028

 


Viscosupplementation is a procedure in which hyaluronic acid (HA) is injected into the knee joint for the treatment of osteoarthritis (OA) of the knee. HA is a naturally occurring glycosaminoglycan and an integral component of synovial fluid and cartilage matrix present in the joints.

Europe viscosupplementation market is estimated to account for US$ 241.8 Mn in terms of value and is expected to reach US$ 343.6 Mn by the end of 2027.

Europe Viscosupplementation Market: Drivers

Increasing prevalence of OA is expected to propel growth of the Europe viscosupplementation market over the forecast period. For instance, according to the study, ‘Prevalence and development of hip and knee osteoarthritis according to American College of Rheumatology criteria in the CHECK cohort’, published in January 2019, in BMC Arthritis Research & Therapy, 63% of the participants in the Netherlands suffered from hip OA and 92% of participants with knee complaints were classified as having knee OA.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to Office of National Statistics, U.K. 2018, there are nearly 12 million people aged 65 and above in the U.K. of which 5.4 million people are aged over 75, 1.6 million are aged over 85, over 500,000 people are over 90, and 14,430 are centenarians.

Three injection cycle held dominant position in Europe viscosupplementation market in 2019, accounting for 59.5% share in terms of value, followed by five injection cycle, and single injection cycle, respectively

Europe Viscosupplementation Market: Opportunities 

R&D related to viscosupplements is expected to offer lucrative growth opportunities for players in Europe viscosupplementation market. For instance, in May 2018, researchers from Humboldt-Universität zu Berlin and Berlin Institute of Health, Germany, reported that HA can influence the cartilage metabolism via upregulation of Metalloproteinase inhibitor 3 in OA-like condition.

In Europe, there has been a rise in the number of osteoarthritis patients seeking alternate options to knee replacement in view of avoiding the side effects associated with NSAID and corticosteroids injections. This factor has changed the overall scenario in the pharmaceuticals industry, propelling the inclination of the players in the market towards the viscosupplementation-based therapy.

 

 

Comments

Popular posts from this blog

Virology Testing Market Detailed In New Research Report 2023

  Virology testing consist of diagnostic methods that help in early detection of the disease such as hepatitis, influenza, HIV, sexually transmitted disease, RCV, and other viral associated disease. Virology testing examines for detection of viral antigens, nucleic acids, and antibodies in the given sample in order to confirm the presence of particular viral infection. There are more than 100 viral diseases identified. Virology Testing Market- Market Dynamics Virology testing market is projected to witness significant growth during forecast period with rising prevalence of virus originated diseases such as flu, hepatitis, AIDS, and STDs, Ebola, Influenza based viral infections, severe acute respiratory syndrome from coronavirus, hemorrhagic fever etc. across world. Early and fast diagnosis of virus infection is very essential to start treatment course. According to the World Health Organization (WHO), January 2018 factsheet, all types of influenza in combination causes annual...

Epidermolysis Bullosa Therapeutics Market Is Booming Worldwide 2023-2028

  Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails. There are three types of epidermolysis bullosa which includes: ·          Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe ·          Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe ·          Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe The type reflects where on the body the blistering ...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

  A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. According to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.  Furthermore, increasing old age population is another driver, which is anticipated to create a high growth scenario for the market. As per the World Population Prospects 2019 revision, the number of people aged 80 years or over is projected to be triple, from 143 million in 2019 to 426 million in 2050. Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications....